Literature DB >> 12658785

Detection of laminin in serum and ascites from patients with epithelial ovarian tumor.

Yongli Chu1, Yuanxian Yang, Meihua Lin, Zehua Wang.   

Abstract

The change in serum laminin (LN) level and its clinical significance in epithelial ovarian tumor were investigated. The LN levels in serum and ascites samples from 69 patients with epithelial ovarian tumor and 42 cases as control group before and after operation were analyzed by radioimmunoassay. The results showed that the serum LN levels in the patients with malignant tumors (157.85 +/- 14.37 ng/ml) were significantly higher than that in the control group (125.14 +/- 7.03 ng/ml) and in the patients with benign tumors (128.36 +/- 8.75 ng/ml) (both P < 0.01) before operation. The serum LN levels in the malignant group were decreased significantly after operation as compared with those before operation (P < 0.05). The serum LN levels in low-differentiated tumors was higher than those in moderate-differentiated tumors and high-differentiated tumors (P < 0.05). The LN levels in ascites (172.94 +/- 15.26 ng/ml) was significantly higher than in serum (161.34 +/- 6.59 ng/ml) (P < 0.05) in malignant tumors. The serum LN levels in the patients with lymph node metastasis (165.41 +/- 19.91 ng/ml) was obviously higher than those without lymph node metastasis (152.35 +/- 10.34 ng/ml) (P < 0.05). It was concluded that LN levels in serum and acistis were remarkably increased in malignant epithelial ovarian tumors, suggesting that LN might be one of important diameters reflecting tumor biological characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658785     DOI: 10.1007/BF02904790

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

1.  Laminin--a glycoprotein from basement membranes.

Authors:  R Timpl; H Rohde; P G Robey; S I Rennard; J M Foidart; G R Martin
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

Review 2.  Still more complexity in mammalian basement membranes.

Authors:  A C Erickson; J R Couchman
Journal:  J Histochem Cytochem       Date:  2000-10       Impact factor: 2.479

Review 3.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

4.  Increased serum concentrations of type IV collagen and laminin associated with granulosa cell tumour of the ovary.

Authors:  M Iwahashi; M Ikoma; T Otani; A Ooshima; R Nakano
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

5.  Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas.

Authors:  R Pellegrini; S Martignone; E Tagliabue; D Belotti; R Bufalino; N Cascinelli; S Ménard; M I Colnaghi
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

6.  Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin.

Authors:  A P Skubitz; R C Bast; E A Wayner; P C Letourneau; M S Wilke
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

7.  Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases.

Authors:  J Kropf; A M Gressner; A Negwer
Journal:  Clin Chem       Date:  1988-10       Impact factor: 8.327

  7 in total
  3 in total

Review 1.  Is there a place for serum laminin determination in patients with liver disease and cancer?

Authors:  Heitor Rosa; Edison Roberto Parise
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

Review 2.  An update of biochemical markers of hepatocellular carcinoma.

Authors:  Abdulaziz Ajlan M AlSalloom
Journal:  Int J Health Sci (Qassim)       Date:  2016-01

Review 3.  The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.

Authors:  Angela Cho; Viive M Howell; Emily K Colvin
Journal:  Front Oncol       Date:  2015-11-02       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.